Evidence map›Paper›PMID 36740717›Full record

Trial reportCritical care (London, England)2023

COVID-19 does not influence functional status after ARDS therapy.

Alice Bernard, Lina Maria Serna-Higuita, Peter Martus, Valbona Mirakaj, Michael Koeppen, Alexander Zarbock, Gernot Marx, Christian Putensen, Peter Rosenberger, Helene Anna Haeberle

Open access · goldAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Critical care (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Diminished plasma levels of GPIb-Frontiers in medicine · 2026
    Trial
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Alice BernardDepartment of Anesthesiology and Intensive Care Medicine, Tübingen University Hospital, Universitätsklinikum Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.
Lina Maria Serna-HiguitaInstitute for Clinical Epidemiology and Applied Biometry, Faculty of Medicine, University of Tübingen, Tübingen, Germany.
Peter MartusInstitute for Clinical Epidemiology and Applied Biometry, Faculty of Medicine, University of Tübingen, Tübingen, Germany.
Valbona MirakajDepartment of Anesthesiology and Intensive Care Medicine, Tübingen University Hospital, Universitätsklinikum Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.
Michael KoeppenDepartment of Anesthesiology and Intensive Care Medicine, Tübingen University Hospital, Universitätsklinikum Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.
Alexander ZarbockDepartment of Anesthesiology, Intensive Care and Pain Medicine, University of Münster, Münster, Germany.
Gernot MarxDepartment of Intensive Care Medicine, University Hospital RWTH Aachen, Aachen, Germany.
Christian PutensenDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany.
Peter Rosenberger *Department of Anesthesiology and Intensive Care Medicine, Tübingen University Hospital, Universitätsklinikum Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany. peter.rosenberger@medizin.uni-tuebingen.de.
Helene Anna Haeberle *Department of Anesthesiology and Intensive Care Medicine, Tübingen University Hospital, Universitätsklinikum Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany. helene.haeberle@medizin.uni-tuebingen.de.
University of Tübingen · DEUniversitätsklinikum Tübingen · DERWTH Aachen University · DEUniversity Hospital Bonn · DEUniversity of Münster · DE

Funding

AKF Program of the University of Tuebingen 414-0-0Deutsche Forschungsgemeinschaft DFG-RO 3671/8-1
6 · The paper itself

Abstract

rationaleHealth-related quality of life after surviving acute respiratory distress syndrome has come into focus in recent years, especially during the coronavirus disease 2019 pandemic.

objectivesA total of 144 patients with acute respiratory distress syndrome caused by COVID-19 or of other origin were recruited in a randomized multicenter trial.

methodsClinical data during intensive care treatment and data up to 180 days after study inclusion were collected. Changes in the Sequential Organ Failure Assessment score were used to quantify disease severity. Disability was assessed using the Barthel index on days 1, 28, 90, and 180. MEASUREMENTS: Mortality rate and morbidity after 180 days were compared between patients with and without COVID-19. Independent risk factors associated with high disability were identified using a binary logistic regression. MAIN

resultsThe SOFA score at day 5 was an independent risk factor for high disability in both groups, and score dynamic within the first 5 days significantly impacted disability in the non-COVID group. Mortality after 180 days and impairment measured by the Barthel index did not differ between patients with and without COVID-19.

conclusionsResolution of organ dysfunction within the first 5 days significantly impacts long-term morbidity. Acute respiratory distress syndrome caused by COVID-19 was not associated with increased mortality or morbidity.

Indexed as

COVID-19Respiratory Distress SyndromeFunctional StatusHumansQuality of LifeSARS-CoV-2Barthel indexCOVID-19Health-related quality of lifeViral pneumonia

Identifiers

PMID36740717
PMCPMC9899507
OpenAlexW4319264702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.